NASDAQ:ADXS - Advaxis Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Advaxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.77 +0.14 (+22.33 %) (As of 12/6/2019 04:00 PM ET) Add Compare Today's Range$0.64Now: $0.77▼$0.7950-Day Range$0.28MA: $0.39▼$0.7752-Week Range$0.21Now: $0.77▼$10.80Volume16.81 million shsAverage Volume2.58 million shsMarket Capitalization$13.21 millionP/E RatioN/ADividend YieldN/ABeta3.43 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ADXS Previous Symbol CUSIPN/A CIK1100397 Webhttp://www.advaxis.com/ Phone609-452-9813Debt Debt-to-Equity RatioN/A Current Ratio8.02 Quick Ratio8.02Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.06 million Price / Sales2.18 Cash FlowN/A Price / Cash FlowN/A Book Value$5.18 per share Price / Book0.15Profitability EPS (Most Recent Fiscal Year)($19.34) Net Income$-66,510,000.00 Net Margins-113.67% Return on Equity-67.08% Return on Assets-47.28%Miscellaneous Employees58 Outstanding Shares17,220,000Market Cap$13.21 million Next Earnings Date1/9/2020 (Estimated) OptionableOptionable Receive ADXS News and Ratings via Email Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ADXS Rates by TradingView Advaxis (NASDAQ:ADXS) Frequently Asked Questions What is Advaxis' stock symbol? Advaxis trades on the NASDAQ under the ticker symbol "ADXS." How were Advaxis' earnings last quarter? Advaxis, Inc. (NASDAQ:ADXS) posted its earnings results on Monday, September, 9th. The biotechnology company reported ($1.00) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.24) by $0.24. The biotechnology company earned $0.01 million during the quarter. Advaxis had a negative return on equity of 67.08% and a negative net margin of 113.67%. View Advaxis' Earnings History. When is Advaxis' next earnings date? Advaxis is scheduled to release their next quarterly earnings announcement on Thursday, January 9th 2020. View Earnings Estimates for Advaxis. What price target have analysts set for ADXS? 1 Wall Street analysts have issued 1-year target prices for Advaxis' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Advaxis' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 421.5% from the stock's current price. View Analyst Price Targets for Advaxis. What is the consensus analysts' recommendation for Advaxis? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Advaxis. Has Advaxis been receiving favorable news coverage? News articles about ADXS stock have trended neutral on Saturday, InfoTrie reports. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Advaxis earned a news impact score of 0.2 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Advaxis. Who are some of Advaxis' key competitors? Some companies that are related to Advaxis include Cyclerion Therapeutics (CYCN), Kezar Life Sciences (KZR), IntelGenx Technologies (IGXT), VERONA PHARMA P/S (VRNA), SUMMIT THERAPEU/S (SMMT), Iterum Therapeutics (ITRM), Humanigen (HGEN), Checkpoint Therapeutics (CKPT), AgeX Therapeutics (AGE), resTORbio (TORC), Savara (SVRA), Moleculin Biotech (MBRX), OASMIA PHARMACE/ADR (OASM), Aridis Pharmaceuticals (ARDS) and Hoth Therapeutics (HOTH). What other stocks do shareholders of Advaxis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Celgene (CELG), Anavex Life Sciences (AVXL), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), ContraVir Pharmaceuticals (CTRV) and Novavax (NVAX). Who are Advaxis' key executives? Advaxis' management team includes the folowing people: Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)Mr. Anthony A. Lombardo, Exec. Officer (Age 70)Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58) Who are Advaxis' major shareholders? Advaxis' stock is owned by many different of institutional and retail investors. Top institutional investors include Sabby Management LLC (8.84%). Company insiders that own Advaxis stock include Anthony A Lombardo, Robert Petit, Roni Appel and Sara Bonstein. View Institutional Ownership Trends for Advaxis. Which institutional investors are buying Advaxis stock? ADXS stock was acquired by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Advaxis. How do I buy shares of Advaxis? Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Advaxis' stock price today? One share of ADXS stock can currently be purchased for approximately $0.77. How big of a company is Advaxis? Advaxis has a market capitalization of $13.21 million and generates $6.06 million in revenue each year. The biotechnology company earns $-66,510,000.00 in net income (profit) each year or ($19.34) on an earnings per share basis. Advaxis employs 58 workers across the globe.View Additional Information About Advaxis. What is Advaxis' official website? The official website for Advaxis is http://www.advaxis.com/. How can I contact Advaxis? Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected] MarketBeat Community Rating for Advaxis (NASDAQ ADXS)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 350 (Vote Outperform)Underperform Votes: 373 (Vote Underperform)Total Votes: 723MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/7/2019 by MarketBeat.com StaffFeatured Article: What is a Real Estate Investment Trust (REIT)?
